Information Provided By:
Fly News Breaks for August 23, 2017
REGN
Aug 23, 2017 | 08:34 EDT
Morgan Stanley analyst Matthew Harrison expects Regeneron's Phase III Dupixent Liberty ASTHMA QUEST readout in September. The key focus will Dupixent's differentiation versus competitors with efficacy regardless of eosinophil count. Harrison sees negative risk/reward for shares given high Street expectations with 15% downside and 5% upside and maintains an Equal Weight with a $450 price target on Regeneron shares.
News For REGN From the Last 2 Days
There are no results for your query REGN